Brett P. Monia, Ph.D.

CEO @ionispharma committed to developing therapeutic breakthroughs. Scientific Advisor @OTSociety. BOD @Ionis & @CogRx. Adjunct Prof @SDSU. Opinions = my own

[Brett P. Monia, Ph.D. @BPMonia]

Looking forward to participating on the Evolving Landscape of Drug Discovery Targeting RNA panel at Biocom California’s Global Life Science Partnering & Investor Conference in La Jolla. Join me at #BiocomGPIC from February 25 – 27. https://t.co/pxJf3pjERH

[Brett P. Monia, Ph.D. @BPMonia]

@JamesTaylor_com Thank you

[James Taylor @JamesTaylor_com]

"I always hesitate to bring my political beliefs into this space. I don’t think my listeners would expect that from me and some of you will find it disappointing: not what you were looking for... "

[1 of 2]

[Ionis @ionispharma]

We’re proud to share that @NEJM today published the positive Phase 3 OASIS-HAE results for our investigational medicine for the treatment of hereditary angioedema (#HAE), which were simultaneously presented at #EAACIcongress. Read the full article: https://t.co/i2ZZBiaSAZ.

[Ionis @ionispharma]

We look forward to sharing new Phase 3 NEURO-TTRansform subgroup data at the 2024 International Symposium on Amyloidosis (ISA) for our medicine for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read more: https://t.co/cegjRSOG1V $IONS

[Ionis @ionispharma]

Today, we shared positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a trial of ION582, an investigational treatment for Angelman syndrome. Updates were presented at the Foundation for Angelman Syndrome Therapeutics Summit.

Learn more: https://t.co/qPGtIK9pNc

[Brett P. Monia, Ph.D. @BPMonia]

Dinner with my long-time friend & science colleague Dr. Jeff Kelly, discoverer of tafamidis. It was great sharing stories about innovation in drug development for ATTR amyloidosis and other diseases.
#innovation #research #leadership

[Brett P. Monia, Ph.D. @BPMonia]

At Ionis, we work every day to give people not only hope, but also much more time with their families to enjoy life. Proud to be partnered with Biogen to deliver Qalsody to patients with SOD1-ALS. https://t.co/8K1hg7rG5L

[Brett P. Monia, Ph.D. @BPMonia]

What a week for IONS and our patients! Reported strong Ph3 data for eplontersen in ATTRv-PN with potential best-in-class profile & now today's FDA approval of QALSODY (tofersen) for SOD1-ALS.  A breakthrough for ALS patients. So proud of my Ionis team! https://t.co/9U2546pMya

[Brett P. Monia, Ph.D. @BPMonia]

Pleased to very successful Phase 3 outcome for our TTR amyloid ASO silencer for ATTRv-PN. Looking forward to our late-breaker presentation at AAN in April!
https://t.co/dF2FqlVYN5

[Brett P. Monia, Ph.D. @BPMonia]

Very pleased with the FDA advisory panel’s unanimous vote in support of tofersen’s accelerated approval for SOD1 ALS. A great day for ALS patients and the ALS community!

[Brett P. Monia, Ph.D. @BPMonia]

Very pleased to have announced today our plans to build a new state of the art manufacturing facility for Ionis. Sets Ionis up well to sustainably deliver life-changing medicines to patients from our industry-leading pipeline for many years to come.
https://t.co/ktRJbRt130

[Brett P. Monia, Ph.D. @BPMonia]

@kelsieswrites @ChrisSnowCGY Awesome picture. So inspirational. Thank you.

[Brett P. Monia, Ph.D. @BPMonia]

Impressive activity for our novel HBV therapy. Can you say “Functional Cures”? Onwards to Phase 3! https://t.co/Qfb6gfb5PX

[Brett P. Monia, Ph.D. @BPMonia]

@kelsieswrites @ChrisSnowCGY @Cmakar8 Awesome! Just totally awesome!

[Kelsie Snow @kelsieswrites]

This night. Unreal. Can’t believe I got myself together after that ovation for @ChrisSnowCGY. It was a core memory kind of night, friends. So grateful. And our our little Crowchild Twin Arena skaters giving fellow CTA skater @Cmakar8 the Norris? incredible. ❤️

[Brett P. Monia, Ph.D. @BPMonia]

Really thrilled with our Phase 3 results for eplontersen in TTR polyneuropathy patients announced this week Impressive efficacy and tolerability across all measures. Another potential breakthrough for patients. https://t.co/hugYgGynZL

[Brett P. Monia, Ph.D. @BPMonia]

Thrilled with the news we shared today about our potential transformational medicine, tofersen for patients suffering from ALS caused by SOD1 mutations. Striking results across many meaningful clinical endpoints! https://t.co/66qIzE6nOq

[Brett P. Monia, Ph.D. @BPMonia]

One of the highlights of my year is to meet with our college summer interns & watch them grow into young leaders. We have a great program that I'm lucky to be involved in & I'm looking forward to meeting the new cohort soon. Be sure to check our website for future opportunities

[Brett P. Monia, Ph.D. @BPMonia]

Volunteering is very near & dear to me. At Ionis, we benefit from two paid days off a year to volunteer in any capacity. We have such great interest in this program & I'm grateful for all our incredible employees who are making huge impacts in our community